Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00077493
Recruitment Status : Suspended (protocol development and Amended protocol revision)
First Posted : February 12, 2004
Last Update Posted : December 28, 2007
Cambridge Antibody Technology
Information provided by:
MedImmune LLC

No Study Results Posted on for this Study
Recruitment Status : Suspended
Estimated Primary Completion Date : October 2008
Estimated Study Completion Date : October 2008